PathAI, a global provider of artificial intelligence-powered technology for pathology, has announced the closing of its US$165 million Series C financing. PathAI will deploy its new capital to accelerate product development while continuing to prioritize the improvement of patient outcomes with reliable AI-powered technology and meaningful collaboration with pharmaceutical and diagnostic partners.
Latham & Watkins LLP represented PathAI in the financing with an emerging companies deal team led by Boston partner Stephen Ranere, with associate Samantha Gross.
LEGAL DESIRE NEWSLETTER
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.